v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 110 $ 868
Expenses:    
Cost of product revenues 32 44
Research and development 15,781 13,482
Selling, general and administrative 6,373 6,263
Total expenses 22,186 19,789
Loss from operations (22,076) (18,921)
Other (expense) income:    
Interest (expense) income, net (821) 166
Change in the fair value of derivative liability (35)  
Gain on sale of strategic investments 2,241  
Total other income 1,385 166
Net loss (20,691) (18,755)
Adjustment to carrying value of Series A Preferred Stock 35  
Net loss attributable to common stockholders $ (20,656) $ (18,755)
Net loss attributable to common stockholders per share    
Basic (in dollars per share) $ (0.33) $ (0.49)
Diluted (in dollars per share) $ (0.33) $ (0.49)
Weighted-average shares used in computing net loss attributable to common stockholders per share, basic (in shares) 62,721,869 38,235,409
Weighted-average shares used in computing net loss attributable to common stockholders per share, diluted (in shares) 62,721,869 38,235,409
Comprehensive loss    
Net loss $ (20,691) $ (18,755)
Unrealized loss on marketable securities (100) (15)
Comprehensive loss (20,791) (18,770)
Partnership revenue    
Revenue:    
Total revenue   732
Product revenue    
Revenue:    
Total revenue $ 110 $ 136